Longitudinal Evidence: The Cardiac AI Investment Differentiator

In the high-stakes world of healthcare AI, especially for vertical AI companies, there’s a huge temptation to chase quick market wins. That pressure often makes founders and their investors forget about the hard work of rigorous clinical validation. But for anyone in this space, knowing the difference between a flash-in-the-pan marketing buzz and the kind of adoption that lands you multi-year enterprise contracts is everything. That difference is earned the hard way: through multi-year, peer-reviewed clinical trials that prove you’re building something that lasts.

Why Flashy Marketing Fails in the Clinical Enterprise

Health systems are inherently conservative. They run on evidence, not hype. When a hospital’s value analysis committee reviews a new technology, they aren’t looking at your marketing slicks. They’re looking for data that proves you can improve patient outcomes, make their operations more efficient, or save them money. Unlike consumer tech, where you can get traction with a viral campaign, clinical adoption is a grind. A cardiac AI tool, for example, can’t just announce it’s better. It has to prove it with a methodology that is rigorous, transparent, and can be reproduced by others. This is exactly where the big, horizontal, general-purpose AI platforms fall down. They don’t have the deep, disease-specific focus or the patience for the long tail of clinical validation, so they come in with broad claims but can’t produce the granular, outcomes-based evidence that a health system’s chief of cardiology or CFO demands. They might get a few pilot programs, but they can’t land the long-term, integrated contracts because there’s no solid, peer-reviewed proof. For disease-specific AI health platforms, especially in a life-or-death field like cardiology, the path to sustained enterprise adoption is paved with scientific publications, not press releases.

The Evidence Moat: HeartFlow and Cleerly’s Masterclass in Clinical Validation

If you want to see how a deep, evidence-based approach works, just look at HeartFlow and Cleerly in the cardiac AI space. Both built their competitive moats by investing relentlessly in longitudinal clinical evidence. Their strategies prove a simple truth: in healthcare, the best competitive advantage is a stack of peer-reviewed publications. HeartFlow, which pioneered using AI for CT-derived fractional flow reserve (FFR-CT), spent years building long-term clinical registries. They systematically showed their SaMD had real clinical utility and was cost-effective, running multi-year studies and getting them published in top-tier journals like the Journal of the American College of Cardiology (JACC). It’s this painful commitment to validation that didn’t just get them FDA 510(k) Clearance. It built them a fortress in the market. HeartFlow got its FDA 510(k) clearance for Plaque Analysis and Roadmap Analysis in October 2022, with another for its Next Gen HeartFlow Plaque Analysis algorithm coming in September 2025. The fact that clinical trials for cardiac imaging AI can take years shows how complex this is. But HeartFlow’s method produced the real-world evidence (RWE) that convinced cardiologists and hospital admins to sign on the dotted line, leading to major contract wins. With that evidence, HeartFlow Plaque Analysis now has nationwide coverage from Cigna and UnitedHealthcare. HeartFlow clinical trial data and publications Cleerly is running the same playbook. Focused on AI-driven quantification of coronary plaque, the company is pouring money into multi-center clinical trials. Their strategy isn’t just about diagnostic accuracy. It’s about proving the prognostic power of their tech. By collecting and analyzing data from all kinds of different patients and hospitals, Cleerly is showing it can actually improve risk stratification and help doctors make better treatment decisions. Why does this matter? Because proactively generating this evidence is exactly what you need to do to get CPT Codes and a clear path to reimbursement which is a top concern for any institutional investor. Cleerly’s work earned it FDA Breakthrough Device Designation for its Coronary Artery Disease (CAD) Staging System in March 2024, and its Cleerly ISCHEMIA software received FDA 510(k) clearance in January 2024. This led to CPT Category I codes for its AI-QCT advanced plaque analyses (effective January 2026) and for its ISCHEMIA software (effective January 2024). Now, Medicare is set to cover its AI plaque analysis under CPT code 75577 in early 2026. With that evidence in hand, they also got coverage from major private payers like UnitedHealthcare, Cigna, Aetna, and Humana for medically necessary cases. Cleerly’s focus on publishing in places like the Journal of the American College of Cardiology builds the authority and trust that directly leads to enterprise adoption. Cleerly research and clinical studies These two aren’t accidents. The line between peer-reviewed papers and winning big health system contracts isn’t blurry. It’s a straight one, drawn by establishing credibility and showing you can create real value while de-risking the adoption process for the hospital.

The Ultimate Competitive Moat: A Peer-Reviewed Evidence Base

If you’re a growth-stage founder, the takeaway should be obvious: clinical validation has to be a priority from day one. Getting an initial 510(k) Clearance is just the entry ticket. It’s the bare minimum. The real, lasting value of a vertical AI healthcare company is its ability to constantly generate and publish strong clinical evidence. This is how you build a “data moat” that’s almost impossible for a competitor to cross, because it requires years of dedicated research, patient enrollment, and careful data analysis they can’t just buy or code their way around. If you’re an institutional investor doing due diligence, you have to grill the team on their clinical evidence strategy just as hard as you grill them on their financials. Don’t just check the box on an FDA clearance. You have to ask about their long-term clinical registry plans, their commitment to multi-center trials, and their pipeline of papers for peer-reviewed journals. A company that treats clinical evidence as an ongoing, strategic investment instead of a one-time regulatory task is showing you it’s serious about building an AI-native business with a defensible model. This commitment de-risks the regulatory path, sometimes even qualifying a company for Breakthrough Device Designation, and it provides the foundation for the reimbursement story that leads to higher exit multiples. This isn’t just a good idea. It’s where regulators are heading anyway with the push for GMLP (Good Machine Learning Practice) and the growing focus on real-world evidence. A vertical AI company that gets ahead of this, embedding these practices into its QMS and product development from the start, is building a foundation of trust that will pay off for years.

Methodology and Source Note

We based this analysis on an audit of clinical registry data from clinicaltrials.gov and the publication histories of the top cardiac AI companies, focusing on studies in the Journal of the American College of Cardiology. The perspective here is informed by our work at Vertical AI Health Leaders. Our editorial mission is to systematically compare vertical AI health specialists against the horizontal general-purpose platforms, always using outcomes data to figure out who is actually delivering results in key health categories. Clinicaltrials.gov registry search for cardiac AI